Parkinson’s Disease Foundation

Keapstone Therapeutics created as new virtual biotech for Parkinson’s

Monday, March 20, 2017

The University of Sheffield and Parkinson’s UK have combined forces to create Keapstone Therapeutics. The goal of the newly formed company is to help move research into nuclear factor erythroid 2-related factor 2 (Nrf2) through the development process and, hopefully, into testable treatments for Parkinson’s disease. Parkinson’s disease affects around 1 million people in the U.S. and 127,000 in the U.K.

[Read More]

Pfizer, IBM collaboration on Parkinson’s disease care

Monday, April 11, 2016

Pfizer and IBM have announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient’s disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options.

[Read More]

Smartphone app revolutionizes clinical trial consent and data sharing

Monday, March 14, 2016

Sage Bionetworks, a Seattle-based nonprofit, has released the first six months of data from a new iPhone app that captures the everyday experiences of more than 9,500 study participants. The app, called mPower (Mobile Parkinson’s Observatory for Worldwide, Evidence-based Research), manages and simplifies the research study, from patient recruitment through the enrollment and consent process. It also enables researchers to collect extensive data from patients with and without Parkinson’s disease. Data from the study can be used to assess the ability of mobile apps to improve the paradigm for clinical studies.

[Read More]

PDF, APDA cultivate future Parkinson’s researchers

Friday, October 16, 2015

The Parkinson’s Disease Foundation (PDF) and the American Parkinson Disease Association (APDA) are collaborating on Summer Student Fellowships to support research that will help solve, treat and end Parkinson’s disease. The collaboration expands opportunities for undergraduates and medical students to gain early exposure to careers in Parkinson’s by conducting 10-week research fellowships with established leaders in the field. The collaboration reflects PDF and APDA’s shared commitment to cultivating students’ early interest and leadership in Parkinson’s research.

[Read More]

23andMe, Genentech partner to analyze genomic data for Parkinson’s

Thursday, January 8, 2015

23andMe, a privately held personal genomics and biotechnology company based in Mountain View, Calif., has inked an agreement with Genentech, a member of the Roche Group, to generate whole genome sequencing data for approximately 3,000 people in 23andMe’s Parkinson’s disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson’s disease.

[Read More]